7 Dec

Short Seller Not Backing Down on Aphria

WRITTEN BY Adam Jones

Short seller not backing down

On December 6, Aphria’s (APHQF) short seller, Hindenburg Research, released its Part 2 on what it found to be further malice in the company’s acquisition efforts. In that report, Hindenburg Research pointed to another acquisition made by Aphria by the name of Liberty Health Sciences. According to the research, this acquisition showed a 5 million Canadian dollar gain to Aphria’s insider in a matter of six days.

Short Seller Not Backing Down on Aphria

Damning report

Further, the report pointed out that Aphria’s CEO, Vic Neufeld, was also a part of the “discount round” in which Aphria purchased companies at overpriced valuations. Even more damning was the short seller’s observation that the SEC had alleged that the individuals that Aphria purchased companies from were involved in pump and dump schemes.

According to Hindenburg Research, Aphria acquired Nuuvera, which also included people connected to the newer allegations attached to the latest round of assault by Hindenburg Research.

Tracking goodwill

When a company acquires other companies at a price in excess of fair value of net tangible and intangible assets, the excess is reported as goodwill. In the above chart, we see Aphria’s goodwill has increased significantly to 522 million Canadian dollars from just about 1.2 million Canadian dollars year-over-year. While there could be nothing wrong with this, an impairment of goodwill in the future will likely raise more questions about the company.

Market Realist will continue to track the developments on Aphria. In the meantime, visit Market Realist’s healthcare sector for ongoing updates on other companies (MJ) such as Canopy Growth (WEED), Aurora Cannabis (ACBFF), and Tilray (TLRY).

Latest articles

Goldman Sachs (GS) settled a lawsuit that alleged it rigged bond prices. Also, Deutsche Bank agreed to pay a fine of $15 million to settle a lawsuit.

In the November 15 premarket trading session, Amarin Corporation (AMRN) stock rose more than 7%, caused by the FDA positive decision for Vascepa.

In the November 14 trading session, Aurora Cannabis (ACB) stock fell 12.7% from the previous session during after-hours trading.

Strategy Analytics reported that Apple could lead the 5G smartphone market in 2020, outshining Samsung—the current leader in the global 5G market.

This week has been tough for the cannabis sector. Cronos Group and Canopy Growth reported lower-than-expected earnings, and the sector ETFs dropped.

Yesterday, Argus Research upgraded Uber stock from “hold” to “buy.” Let's look at Uber and Lyft’s recent analyst rating changes.